Manufacturer 340B Restrictions for Oregon

Details
Published: Tuesday, 14 October 2025 08:37
Written by 340B Editor

Oregon House Bill 2385 prohibits drug manufacturers from interfering—directly or indirectly—with pharmacies or drug outlets that acquire, deliver, or dispense 340B drugs to eligible healthcare providers. It also bans manufacturers from requiring utilization review data as a condition for accessing 340B drugs.

 Below is the current status of manufacturer restrictions for Oregon.

Manufacturer Name

Specific Drugs

Current CP Policy - CE Applicability

CP Policy Original Effective Date

CP Policy Original Notice Date

CP Policy - Date first applied to FQHC's

OR Exemption Announcement date

OREGON Exempted  Date

Single CP Designation Allowed?

CP Rx Data Submission Req to 340BESP?

Biogen

All

OR Exempted

2/1/2023

12/1/2022

12/19/24

9/22/25

9/26/25

Yes

Yes

Boehringer Ingelheim

All

OR Exempted

8/1/2021

6/30/2021

9/1/22

8/19/25

9/26/25

Yes

Yes

Liquidia

All

OR Exempted

3/1/2024

3/1/2024

3/1/24

9/24/25

9/26/25

Yes

Yes

Merck

All

OR Exempted

9/1/2021

8/1/2021

5/31/22

9/22/25

9/26/25

Yes

Yes

Organon

All

OR Exempted

7/1/2023

6/1/2023

7/1/23

10/7/25

9/29/25

Yes

Yes

Alkermes

All

OR Exempted

7/22/2024

6/4/2024

7/22/24

8/22/25

9/1/25

Yes

No

GlaxoSmithKline

All

OR Exempted

4/1/2022

2/1/2022

5/1/23

9/12/25

9/28/25

Yes

No

GlaxoSmithKline

GSK - Benlysta

OR Exempted

4/1/2022

2/1/2022

5/1/23

9/12/25

9/28/25

Yes

No

GlaxoSmithKline

GSK - Flolan

OR Exempted

4/1/2022

2/1/2022

5/1/23

9/12/25

9/28/25

Yes

No

GlaxoSmithKline

GSK - Nucala

OR Exempted

4/1/2022

2/1/2022

5/1/23

9/12/25

9/28/25

Yes

No

GlaxoSmithKline

GSK - Ojjaara

OR Exempted

4/1/2022

2/1/2022

5/1/23

9/12/25

9/28/25

Yes

No

GlaxoSmithKline

GSK - Zejula

OR Exempted

4/1/2022

2/1/2022

5/1/23

9/12/25

9/28/25

Yes

No

Sobi

All

OR Exempted

7/1/2024

6/3/2024

6/3/2024

9/24/25

9/26/25

Yes

No

UCB

All

OR Exempted

12/13/2021

11/1/2021

10/24/24

10/13/25

10/13/25

Yes

No

Teva

All

OR Exempted

7/5/2023

6/8/2023

n/a

9/24/25

9/28/25

N/A

N/A

Abbvie
(Abbott, Allergan, Actavis, Forest/Allergan)

All

FQHC

2/1/2022

12/1/2021

?

Yes

Yes

AstraZeneca

All

FQHC

10/1/2020

8/17/2020

10/1/20

Yes

Yes

Bayer

All

FQHC

3/1/2023

2/1/2023

6/24/24

Yes

Yes

Bristol Myers Squibb

All

FQHC

3/1/2022

1/14/2022

7/1/24

Yes

Yes

Bristol Myers Squibb

Bristol Myers Squibb -  LMiD

FQHC

3/1/2022

1/14/2022

7/1/24

Yes

Yes

Bristol Myers Squibb

Bristol Myers Squibb - Camzyos

FQHC

3/1/2022

1/14/2022

7/1/24

Yes

Yes

Bristol Myers Squibb

Bristol Myers Squibb - Krazati

FQHC

3/1/2022

1/14/2022

7/1/24

Yes

Yes

Eli Lilly

All

FQHC

7/1/2020

6/1/2020

7/1/20

Yes

Yes

Exelixis

All

FQHC

7/6/2022

6/1/2022

7/6/22

Yes

Yes

Gilead

All

FQHC

5/2/2022

3/1/2022

5/2/22

Yes

Yes

Mitsubishi Tanabe Pharma America

All

FQHC

10/1/2025

9/2/2025

10/2/25

Yes

Yes

Novo Nordisk

All

FQHC

1/1/2021

12/1/2020

7/1/24

Yes

Yes

United Therapeutics

All

FQHC

11/20/2020

11/18/2020

11/20/20

Yes

Yes

Amgen

All

FQHC

1/3/2022

12/21/2021

3/19/24

Yes

No

Bausch + Lomb*

All

FQHC

7/1/2024

6/5/2024

7/1/24

Yes

No

Bausch Health*

All

FQHC

4/1/2020

4/1/2020

4/1/20

Yes

No

EMD SERONO INC

All

FQHC

3/1/2023

2/1/2023

3/1/2023

Yes

No

Novartis

All

FQHC

10/1/2020

8/17/2020

?

Yes

No

Sumitomo

All

FQHC

5/1/2024

4/1/2024

5/1/2024

Yes

No

Sumitomo

Sumitomo - Orgovyx

FQHC

5/1/2024

4/1/2024

5/1/2024

Yes

No

Viatris

All

FQHC

8/1/2024

7/1/2024

8/1/2024

Yes

No

Sanofi

All

FQHC

10/1/2020

8/1/2020

10/1/20

No

No

 *Manufacturer Withdrawn From 340B Program.

Graph courtesy of Marcus Cox, RPh,  Chief Pharmacy Officer, Klamath Health Partnership, Inc, Oregon